Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (447)	12/24/2000 12:50:49 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

meanwhile, back at the ranch..... core patent issues, first claim sounding great......... US6159705: Recombinant yeast cells for identifying receptor effectors Inventor(s): Trueheart; Joshua , Concord, MA Paul; Jeremy I. , Nyack, NY Fuernkranz; Hans A. , San Jose, CA Nathan; Debra , Mt. Kisco, NY Holmes; Scott , Middlebury, CT Applicant(s): Cadus Pharmaceutical Corporation, New York, NY Issued/Filed Dates: Dec. 12, 2000 / Sept. 24, 1997 Application Number: US1997000936632 Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. The subject assay is particularly amenable for identifying surrogate ligands for receptors especially from small molecule or peptide libraries or from peptides produced by an autocrine system. What is claimed is: 1. An assay for identifying a compound that modulates a heterologous receptor expressed by a yeast cell comprising: i) providing a yeast cell which expresses a heterologous receptor which is functionally integrated into an endogenous yeast signaling pathway, wherein said yeast cell comprises an endogenous gene operatively linked to a heterologous promoter at the natural location of said endogenous gene in said yeast cell, said promoter being responsive to signals produced by said yeast signaling pathway; ii) contacting the yeast cell with a test compound; and iii) detecting an alteration in a signal produced by the endogenous yeast gene; to thereby identify a compound that modulates the heterologous receptor.